Cutaneous α-Synuclein Pathology as a Differential Marker: A Histological and Statistical Comparison across Neurodegenerative Disease Groups
Authors:
- Dorota ŠebelováDŠDorota Šebelová
- KateřIna MenšíkováKMKateřIna Menšíková
- Michaela KaiserováMKMichaela Kaiserová
- Lenka SatkeLSLenka Satke
- Zuzana GrambalováZGZuzana Grambalová
- KateřIna ČížkováKČKateřIna Čížková
- Zdeněk TauberZTZdeněk Tauber
- KateřIna KlíčováKKKateřIna Klíčová
- Dominik HrabošDHDominik Hraboš
- Sarah E. V. CookSCSarah E. V. Cook
- Jana ZapletalováJZJana Zapletalová
- Petr KaňovskýPKPetr Kaňovský
Open Access
- 21 February 2026
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 37
Abstract
There is an urgent need for early and accurate biomarkers of neurodegenerative disorders. Due to the high innervation and accessibility of the skin, a skin biopsy is a minimally invasive method of detecting phosphorylated α-synuclein (p-α-syn) and assessing intraepidermal nerve fiber density (IENFD). We analyzed biopsies taken from the back and the leg of patients with parkinsonian syndromes (Park.sy.), α-synucleinopathies, multiple system atrophies (MSA), tauopathies, and other neurological disorders, as well as from healthy controls. Double immunofluorescence was performed for p-α-syn (Ser129) and protein gene product 9.5 (PGP 9.5), alongside quantitative IENFD assessment. p-α-syn was significantly more prevalent in the patient groups than in the control group. The highest prevalence was observed in patients with parkinsonian syndromes, α-synucleinopathies and MSA. Tauopathies showed preferential paravertebral positivity. Reduction or absence of IENFD was most pronounced in tauopathies (75%), while IENFD was most commonly preserved in MSA (83.3%), indicating that disease-specific patterns of peripheral nerve involvement are exhibited. p-α-syn positivity was found to correlate with shorter disease duration, suggesting its potential as an early biomarker. Combined with olfactory testing, cutaneous markers improved diagnostic discrimination. Our findings support the use of skin biopsies as a promising clinical tool in diagnosing biomarker-based neurodegenerative diseases.Keywords
Funding Information
- Palacký University Olomouc
This publication has 52 references indexed in Scilit:
- Utilization of Skin Punch Biopsy for the Diagnosis of α‐Synucleinopathy in Clinical PracticeMovement Disorders Clinical Practice, 2025
- Skin α-synuclein assays in diagnosing Parkinson’s disease: a systematic review and meta-analysisJournal of Neurology, 2025
- Skin Biopsy May Help to Distinguish Multiple System Atrophy–Parkinsonism from Parkinson's Disease With Orthostatic HypotensionMovement Disorders, 2020
- Value of in vivo α‐synuclein deposits in Parkinson's disease: A systematic review and meta‐analysisMovement Disorders, 2019
- Cervical skin denervation associates with alpha‐synuclein aggregates in Parkinson diseaseAnnals of Clinical and Translational Neurology, 2018
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017
- Skin nerve misfolded α‐synuclein in pure autonomic failure and Parkinson diseaseAnnals of Neurology, 2015
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophyMovement Disorders, 2015
- Cutaneous neuropathy in Parkinson’s disease: a window into brain pathologyActa Neuropathologica, 2014